Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Analysts

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $13.20.

A number of equities research analysts have recently issued reports on IMUX shares. B. Riley reiterated a "buy" rating and issued a $6.00 target price on shares of Immunic in a research note on Wednesday, April 16th. StockNews.com downgraded shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Immunic in a research report on Thursday, May 1st. William Blair reaffirmed an "outperform" rating on shares of Immunic in a report on Friday. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $17.00 price target on shares of Immunic in a research note on Wednesday, April 30th.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently modified their holdings of the business. HB Wealth Management LLC bought a new stake in shares of Immunic during the 4th quarter valued at about $81,000. Renaissance Technologies LLC grew its holdings in shares of Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after purchasing an additional 177,542 shares during the last quarter. Invesco Ltd. bought a new position in shares of Immunic during the fourth quarter valued at approximately $37,000. Barclays PLC acquired a new stake in shares of Immunic during the 4th quarter worth approximately $84,000. Finally, Focus Partners Wealth lifted its holdings in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after purchasing an additional 23,610 shares during the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $0.96 on Friday. The business has a 50-day moving average of $1.06 and a two-hundred day moving average of $1.08. The firm has a market capitalization of $92.08 million, a PE ratio of -0.78 and a beta of 1.73. Immunic has a 12 month low of $0.83 and a 12 month high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25). As a group, research analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.